Diversity of Antibody Binding to V3 Peptides Representing Consensus Sequences of HIV Type 1 Genotypes A to E: An Approach for HIV Type 1 Serological Subtyping

Barin, Françis; Lahbabi, Yousra; Buzelay, Laurence; Lejeune, Bernard; Baillou-Beaufils, Armelle; Denis, F.; Mathiot, C; Mboup, Souleymane; Vithayasai, Vicharn; Dietrich, Ursula; Goudeau, Alain

doi:10.1089/aid.1996.12.1279

Cited by 93 publications

(63 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The viruses were characterized for group and subtype by molecular (n ϭ 214) or serotyping (n ϭ 166) analysis as described previously (15,16) The Abbott Architect assay is also a chemiluminescent magnetic microparticle-based immunoassay, with a run time of 28 min. The assay is used to determine the presence of HIV-1 p24 antigen and antibody to HIV-1 group M, HIV-1 group O, and HIV-2 using an automated, random-access instrument.…”

Section: Methodsmentioning

confidence: 99%

Performance of the Liaison XL Murex HIV Ab/Ag Test on Clinical Samples Representing Current Epidemic HIV Variants

et al. 2014

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Performance of the Liaison XL Murex HIV Ab/Ag Test on Clinical Samples Representing Current Epidemic HIV Variants

et al. 2014

View full text Add to dashboard Cite

“…The sequences were previously described (6,31,32). We did not feel that it was necessary to add other peptides due to the extensive cross-reactivity between the V3 sequences of these clades and other clades (31,32).…”

Section: Methodsmentioning

confidence: 99%

“…We did not feel that it was necessary to add other peptides due to the extensive cross-reactivity between the V3 sequences of these clades and other clades (31,32). Antibodies to these consensus sequences are detectable in most infected people a few months after seroconversion (6,27,30).…”

Section: Methodsmentioning

confidence: 99%

Development and Validation of an Immunoassay for Identification of Recent Human Immunodeficiency Virus Type 1 Infections and Its Use on Dried Serum Spots

et al. 2005

Self Cite

View full text Add to dashboard Cite

The objective was to develop and to validate an immunossay to identify recent human immunodeficiency virus type 1 (HIV-1) infections that can be used on dried serum spots (DSS). A single, indirect enzyme-linked immunosorbent assay was developed to quantify antibodies toward four HIV-1 antigens: consensus peptides of the immunodominant epitope of gp41 (IDE), consensus V3 peptides, recombinant integrase, and recombinant p24. The parameters of the logistic regression used to classify the samples were estimated on a training sample (210 serum samples) using resampling techniques to get stable estimates and then applied to a validation sample (761 serum samples). The IDE and V3 peptides were the best able to discriminate between the antibodies present in serum from recently (<6 months) infected individuals and those with long-lasting infection. Combined quantification of antibody binding to these two synthetic antigens allowed us to identify recent infections with an area under the receiver operating characteristic curve of 0.949 and a sensitivity of 88.3%, with a specificity of 97.6% in patients with long-term infection (but not AIDS) and 86.0% in patients suffering from AIDS with a threshold of 0.50 in the validation sample. This simple immunoassay can be used to identify recently HIV-1-infected patients. Its performance is compatible with its use in population-based studies including DSS.The human immunodeficiency virus (HIV) epidemic is generally assessed by monitoring seroprevalence i.e., the proportion of persons with HIV antibodies (including recently infected people and people who were infected several years previously). To understand recent changes in the HIV epidemic, it is necessary to estimate the incidence, i.e., the number of newly infected subjects in a defined period. A strategy based on a sensitive/less sensitive testing algorithm was recently used to identify serum samples from recently infected individuals (16). This strategy that uses both a sensitive and a less-sensitive enzyme immunoassay (S/LS EIA), also called a detuned assay, was applied to various situations, providing estimates of HIV incidence (12,14,16,18,24,33,35). One of the major drawbacks of this strategy is that the test is an adaptation of a commercial EIA, which poses problems for long-term availability. It is therefore necessary to develop and to validate simple immunoassays that can continuously be used independent of any commercial source. The knowledge of the anti-HIV type 1 (anti-HIV-1) antibody response (5,8,20,38) and recent studies aimed at identifying antigens to distinguish recent infections (27, 30) allowed us to design a candidate assay to assess persons with recent infection. We report the development and the validation of this assay for the identification of recent HIV-1 infections (EIA-RI) and its application to dried blood spots.

show abstract

“…Previous studies using synthetic peptides derived from V3 sequences have given variable results in their ability to distinguish HIV-1 subtypes (12-15). Our modified V3 EIA showed similar sensitivity and specificity for some HIV-1 subtypes (14)(15)(16)(17). Thus, V3 serology may be more reliable to evaluate the distribution of the intrasubtype strains, such as the Brazilian or Thai B variants.…”

Section: Discussionmentioning

confidence: 73%

Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity

Casseb

Katzenstein

Winters

et al. 2002

Braz J Med Biol Res

View full text Add to dashboard Cite

The main objective of the present study was to assess the specificity and sensitivity of a modified assay using short synthetic peptides of the V3 region of HIV-1 gp120, which is the main target for neutralizing antibodies. Results from an enzyme immunoassay (EIA) employing a panel of synthetic peptides of HIV-1 subtypes and using urea washes to detect high avidity antibodies (AAV3) were compared with those obtained by the heteroduplex mobility assay and DNA sequencing. The EIA correctly typed 100% of subtype B (sensitivity = 1.0; specificity = 0.95), 100% of HIV-1 E samples (sensitivity = 1.0; specificity = 1.0), and 95% of subtype C specimens (sensitivity = 0.95; specificity = 0.94). In contrast, only 50% of subtype A (sensitivity = 0.5; specificity = 0.95), 60% of subtype D (sensitivity = 0.6; specificity = 1.0), and 28% of subtype F samples (sensitivity = 0.28; specificity = 0.95) were correctly identified. This approach was also able to discriminate in a few samples antibodies from patients infected with B variants circulating in Brazil and Thailand that reacted specifically. The assays described in this study are relatively rapid and simple to perform compared to molecular approaches and can be used to screen large numbers of serum or plasma samples. Moreover, the classification in subtypes (genotypes) may overestimate HIV-1 diversity and a classification into serotypes, based on antigenic V3 diversity or another principal neutralization domain, may be more helpful for vaccine development and identification of variants.

show abstract

Diversity of Antibody Binding to V3 Peptides Representing Consensus Sequences of HIV Type 1 Genotypes A to E: An Approach for HIV Type 1 Serological Subtyping

Cited by 93 publications

References 24 publications

Performance of the Liaison XL Murex HIV Ab/Ag Test on Clinical Samples Representing Current Epidemic HIV Variants

Performance of the Liaison XL Murex HIV Ab/Ag Test on Clinical Samples Representing Current Epidemic HIV Variants

Development and Validation of an Immunoassay for Identification of Recent Human Immunodeficiency Virus Type 1 Infections and Its Use on Dried Serum Spots

Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity

Contact Info

Product

Resources

About